Phathom Pharmaceuticals, Inc. (PHAT) Form 8-K — Oct 29, 2026
Phathom Pharmaceuticals reported Q3 2026 net revenue of $84.7 million, up 71% year over year and 14% sequentially, with over 2 million VOQUEZNA prescriptions filled since launch. The company generated positive operating cash flow for the second consecutive quarter and posted non-GAAP adjusted net income of $3.0 million versus an $11.2 million adjusted loss a year ago. GAAP net loss narrowed sharply to $13.9 million from $30.0 million, and cash of $184.6 million rose $2.1 million sequentially. Management reaffirmed full-year 2026 guidance of $310-325 million in net revenue and said it expects no need for additional debt or equity financing.
Key figures
- Revenue
- 84700000
- Guidance
- FY2026 net revenue $310-325M; gross-to-net discount 55-59%; gross margin ~80%; non-GAAP operating expenses (ex-SBC) $235-245M
- Revenue Yoy
- 71%
- Total Assets
- 345020000
- Cash Position
- 184558000
- Gross profit q3
- 66355000
- Q3 2025 revenue
- 49500000
- Q3 prescriptions
- approximately 380,000 (248,000 covered; 132,000 cash-pay)
- Nine month revenue
- 217297000
- R and d expense q3
- 8745000
- Sg and a expense q3
- 57695000
- Sequential revenue growth
- 14%
- Total prescriptions filled
- over 2 million through October 16, 2026
- Non gaap adjusted net income q3
- 2986000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.